Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11775346rdf:typepubmed:Citationlld:pubmed
pubmed-article:11775346lifeskim:mentionsumls-concept:C0011849lld:lifeskim
pubmed-article:11775346lifeskim:mentionsumls-concept:C0171023lld:lifeskim
pubmed-article:11775346lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:11775346lifeskim:mentionsumls-concept:C0085973lld:lifeskim
pubmed-article:11775346lifeskim:mentionsumls-concept:C0007320lld:lifeskim
pubmed-article:11775346pubmed:issue10lld:pubmed
pubmed-article:11775346pubmed:dateCreated2002-1-1lld:pubmed
pubmed-article:11775346pubmed:abstractTextAtypical antipsychotics are widely used in psychotic disorders, refractory to conventional neuroleptic agents. They induce minimal extra pyramidal side effects, probably due to their greater affinity for certain dopaminergic receptors. However, this polyreceptor affinity may be responsible for the development of other side effects. We report a 48 years old male drinker and addicted to cocaine, that after two months of Olanzapine use, developed a severe diabetes mellitus with fasting blood glucose values reaching 514 mg/dl. When he was admitted to the hospital, physical examination was normal and his body mass index was 28 kg/m2. Olanzapine was discontinued and blood glucose values gradually returned to normal. After two months of follow up, the patient is on dietary treatment and with a fasting glucose of 132 mg/dl.lld:pubmed
pubmed-article:11775346pubmed:languagespalld:pubmed
pubmed-article:11775346pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11775346pubmed:citationSubsetIMlld:pubmed
pubmed-article:11775346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11775346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11775346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11775346pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11775346pubmed:statusMEDLINElld:pubmed
pubmed-article:11775346pubmed:monthOctlld:pubmed
pubmed-article:11775346pubmed:issn0034-9887lld:pubmed
pubmed-article:11775346pubmed:authorpubmed-author:RojasPPlld:pubmed
pubmed-article:11775346pubmed:authorpubmed-author:VarelaSSlld:pubmed
pubmed-article:11775346pubmed:authorpubmed-author:ArancibiaPPlld:pubmed
pubmed-article:11775346pubmed:authorpubmed-author:BravoVVlld:pubmed
pubmed-article:11775346pubmed:issnTypePrintlld:pubmed
pubmed-article:11775346pubmed:volume129lld:pubmed
pubmed-article:11775346pubmed:ownerNLMlld:pubmed
pubmed-article:11775346pubmed:authorsCompleteYlld:pubmed
pubmed-article:11775346pubmed:pagination1183-5lld:pubmed
pubmed-article:11775346pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:meshHeadingpubmed-meshheading:11775346...lld:pubmed
pubmed-article:11775346pubmed:year2001lld:pubmed
pubmed-article:11775346pubmed:articleTitle[Diabetes mellitus induced by olanzapine. A case report].lld:pubmed
pubmed-article:11775346pubmed:affiliationSección Endocrinología, Departamento de Medicina y Laboratorio de Endocrinología, Hospital Clínico Universidad de Chile, Clínica Psiquiátrica, Universidad de Chile. paularojas@mimail.cllld:pubmed
pubmed-article:11775346pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11775346pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:11775346pubmed:publicationTypeCase Reportslld:pubmed